Latest News

  • PARTNERSHIPS

    13 Jan 2026

    AI Alliance Refines RNA Cancer Drug Discovery

  • INVESTMENT

    12 Jan 2026

    A New Pulse in Biotech IPOs Starts With Oncology

  • TECHNOLOGY

    7 Jan 2026

    Can Generative AI Crack the Code of mRNA Design?

  • RESEARCH

    19 Dec 2025

    A New Twist Makes mRNA Drugs More Selective

BARDA Pullback Signals New Phase for US mRNA Development

HHS press release signaling reduced BARDA support for mRNA development

REGULATORY

18 Dec 2025

HHS is winding down BARDA-backed mRNA vaccine programs, prompting analysts to see a shift toward commercially focused mRNA strategies

Automated production line filling COVID-19 vaccine vials in a sterile facility.

INSIGHTS

24 Nov 2025

Moderna’s Homegrown Bet Could Rewire Biotech’s Future

Moderna boosts US mRNA production, strengthening supply chains as firms like Pfizer explore on shore manufacturing

3D illustration of an mRNA lipid nanoparticle releasing RNA strands into surrounding molecules.

REGULATORY

20 Nov 2025

US MRNA Leaders Push for Regulatory Modernization as Innovation Surges

Moderna, Replicate, and others accelerate mRNA advances as the US faces rising pressure to update its regulatory approach

Technicians working in an mRNA bioprocessing lab with stainless steel bioreactors.

PARTNERSHIPS

18 Nov 2025

New Alliance Aims to Steady the mRNA Supply Chain

Wacker Biotech and RNAV8 Bio join forces to streamline mRNA development and create a more predictable path to the clinic

mRNA strand connecting to virus and syringe representing genetic therapy

INNOVATION

14 Nov 2025

Can mRNA Rewrite the Future of Rare Disease Care?

US labs and biotech firms push mRNA deeper into rare disease therapy, stirring hope and investment

3D illustration of an mRNA strand, syringe, and virus particle symbolizing mRNA research.

INSIGHTS

10 Nov 2025

What BioNTech’s CureVac Deal Says About mRNA’s Future

BioNTech’s $1.25B CureVac deal pushes mRNA beyond vaccines toward cancer treatment

AbbVie corporate building exterior symbolizing major expansion into in-vivo mRNA therapies

PARTNERSHIPS

20 Aug 2025

Inside AbbVie's High-Stakes Deal on Next-Gen mRNA Therapy

AbbVie's Capstan buy signals a bold leap into in-vivo mRNA therapies, reshaping the race for next-gen autoimmune treatments.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.